Mode
Text Size
Log in / Sign up
Phase 2 N=29 Randomized Triple-blind Prevention

Does Nesiritide Provide Renal Protection

Renal Failure

Enrolled (actual)
29
Serious AEs
10.3%
Results posted
Mar 2014
Primary outcome: Primary: Measure Neutrophils to Measure Kidney Injury — 5.453; 5.630; 4.508; 4.546 log2 expression

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Nesiritide (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Florida
Primary completion
Dec 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Measure Neutrophils to Measure Kidney Injury
5.453; 5.630; 4.508; 4.546; 5.501; 5.444
PRIMARY
The Examine and Measure Cytokines to Measure Kidney Injury
1.750; 1.959; 28.167; 63.930; 33.457; 57.412
PRIMARY
The Examine and Measure Endothelin-1 to Measure Kidney Injury
1.778; 1.239; 2.096; 2.283; 1.670; 2.068
PRIMARY
The Examine and Measure Urinary NGAL to Measure Kidney Injury
124.566; 33.766

Summary

This project evaluates whether nesiritide, human recombinant brain natriuretic peptide, confers renal protection during cardiovascular surgery by attenuating the inflammatory response.

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing surgery on their aortic arch, ascending aorta, or having aortic valve or mitral valve surgery
  • Baseline MDRD (modification of diet in renal disease) calculated GFR (Glomerular Filtration Rate) 30-90 ml/min.
  • Signed Informed Consent

Exclusion Criteria

  • Age 80
  • Ejection Fraction <30%.
  • Presence of endocarditis or other infection.
  • Presence or anticipated use of an intra-aortic balloon pump.
  • History of an organ transplant.
  • History of an adverse reaction to nesiritide.
  • Surgery performed without cardiopulmonary bypass.
  • Receiving Aprotinin
  • Dopamine administered in doses <5 mcg /kg min.
  • Women of child bearing potential or pregnant or breastfeeding.
  • Participation in any other investigational trial
  • Jehovah Witness
  • Bleeding Disorder
  • Active Endocarditis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01440881). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search